论文部分内容阅读
本文采用美国Abbott公司、上海科华公司生产的抗—HCV药盒,病毒所抗—HDV HDAg药盒,以及本所生产的乙型肝炎药盒;测定了本所住院的不同肝病病人血清标本135例,其中肝硬化58例,肝癌34例,重症肝炎13例,慢活肝18例,慢迁肝12例。结果发现HCV感染,肝硬化50％,肝癌为41.1％,重症肝炎为15.3％,慢活肝为11.1％,肝硬化、肝癌明显大于其它组,P<0.01;HDV感染:肝硬化17.2％,肝癌11.7％,重症肝炎30.7％,慢活肝22.2％,重症肝炎、慢活肝组高于其它各组。
In this paper, the United States Abbott Company, Shanghai Kehua company’s anti-HCV kit, anti-HDV virus anti-HDV kit, as well as the production of hepatitis B kit; measured in our hospital in patients with different liver disease serum samples 135 Cases, of which 58 cases of liver cirrhosis, liver cancer in 34 cases, 13 cases of severe hepatitis, 18 cases of slow-living liver, 12 cases of slow-moving liver. The results showed that HCV infection, cirrhosis 50%, liver cancer was 41.1%, severe hepatitis was 15.3%, slow-living liver was 11.1%, cirrhosis, liver cancer was significantly greater than other groups, P <0.01; HDV infection: liver cirrhosis 17.2% 11.7%, severe hepatitis 30.7%, slow living liver 22.2%, severe hepatitis, chronic active liver group than the other groups.